Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $1.8 million.

  • Cartesian Therapeutics' Change in Account Payables rose 17366.67% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 153148.15%. This contributed to the annual value of -$2.9 million for FY2024, which is 20328.16% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Change in Account Payables of $1.8 million as of Q3 2025, which was up 17366.67% from -$1.6 million recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Change in Account Payables high stood at $2.8 million for Q4 2023, and its period low was -$2.4 million during Q3 2024.
  • Over the past 5 years, Cartesian Therapeutics' median Change in Account Payables value was $85000.0 (recorded in 2023), while the average stood at $93631.6.
  • Per our database at Business Quant, Cartesian Therapeutics' Change in Account Payables crashed by 478214.29% in 2021 and then surged by 405000.0% in 2023.
  • Cartesian Therapeutics' Change in Account Payables (Quarter) stood at -$1.4 million in 2021, then skyrocketed by 107.46% to $102000.0 in 2022, then soared by 2643.14% to $2.8 million in 2023, then tumbled by 108.47% to -$237000.0 in 2024, then soared by 845.99% to $1.8 million in 2025.
  • Its Change in Account Payables stands at $1.8 million for Q3 2025, versus -$1.6 million for Q2 2025 and $1.8 million for Q1 2025.